Innovair

Beclometasone dipropionate / formoterol fumarate, the active ingredient in Innovair, is an inhaled corticosteroid/long‑acting beta2‑agonist combination presented as a dose inhalation aerosol (metered‑dose inhaler) for inhalation use. It provides maintenance therapy for asthma and chronic obstructive pulmonary disease in adults and adolescents.

GNH USA supplies Innovair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent quality for global respiratory care programs and ensuring timely delivery across diverse markets.

Innovair, a combined inhaled corticosteroid and long‑acting beta2‑agonist, is used in the maintenance treatment of obstructive airway diseases.

Asthma: Improves long‑term control of symptoms and reduces the frequency of exacerbations in patients with persistent asthma. Severe asthma: Allows step‑up therapy for individuals not adequately controlled on inhaled corticosteroid alone. COPD: Provides bronchodilation and anti‑inflammatory effects to help reduce COPD exacerbations and improve lung function.

The most frequently reported adverse reactions with Innovair are related to local airway irritation and systemic exposure to the corticosteroid component.

Common Side Effects: - Oral candidiasis: fungal infection of the mouth or throat, often presenting as white patches and discomfort. - Hoarseness: voice changes after inhalation, usually temporary and related to local irritation. - Throat irritation: discomfort or soreness in the throat, which may be reduced by rinsing the mouth after use.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing shortly after inhalation, requiring immediate medical attention. - Adrenal suppression: reduced cortisol production with prolonged use, potentially leading to fatigue, weakness, or hypotension. - Severe allergic reaction: anaphylaxis, angioedema, or urticaria that may manifest as swelling, rash, or difficulty breathing.

Before prescribing Innovair, clinicians should consider several precautionary measures to ensure safe and effective use.

Assess infection risk: Screen for active respiratory infections such as tuberculosis before initiating therapy. Monitor growth in children: Regularly measure height in pediatric patients to detect potential growth suppression. Review cardiovascular status: Use caution in patients with arrhythmias, hypertension, or coronary artery disease. Avoid abrupt discontinuation: Gradually taper the dose after long‑term use to prevent adrenal insufficiency. Educate on inhaler technique: Instruct patients to rinse mouth after each dose to minimize oral candidiasis. Store at ambient temperature: Keep inhaler in the original container, protect from moisture and heat, and store below 25°C.

Innovair may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator effect and precipitate bronchospasm. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase systemic corticosteroid exposure, raising risk of adrenal suppression. - Monoamine oxidase inhibitors (MAOIs): can potentiate cardiovascular effects of the LABA component.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypokalemia caused by beta‑agonist activity. - Theophylline: additive stimulant effect on the heart, requiring monitoring of cardiac status. - Other inhaled corticosteroids: concurrent use can increase risk of systemic corticosteroid side effects.